Sep. 13 at 4:57 PM
$DVAX Success can be more convincing than words. The rationale for Infant HepB jabs is under consideration this week by the ACIP.
This chart demonstrates the past wisdom for the shots. And, it helps to inform the advantage of Universal adult HepB jabs going forward.
BioTech investing requires nerves of steel and the wisdom to only risk what you can afford to lose.
The ACIP might bless Heplisav for the lack of Alum. Or, they may literally throw the baby out with the bath water by denying Infant HepB jabs; plus, damming all HepB shots as only needed by drug and sex addicted undeserving adults.
My opinion is that Management needs to expand outside the USA. But that is not on the list of projects, sadly.
